Goldman Sachs initiates Insmed stock coverage with buy rating, $188 target
AI Summary
Goldman Sachs has initiated coverage on Insmed stock with a buy rating and set a target price of $188, signaling confidence in the company's market potential.
Related Articles
US releases additional $267m to combat Ebola outbreak
Punch Nigeria —
BlackBerry lifts annual revenue forecast on strength in automotive software business
Investing.com —
Meta’s Charm gadget carries CEO Zuckerberg’s big AI ambitions
Investing.com —
Starbucks to close about 1% of coffeehouses in North America
Investing.com —
BofA initiates MGE Energy stock coverage with neutral rating
Investing.com —
TD Synnex earnings beat by $1.04, revenue topped estimates
Investing.com —